Celldex believes that the cash, cash equivalents and marketable securities at December 31, 2023 are sufficient to meet estimated working capital requirements and fund current planned operations into 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CLDX:
- Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
- Celldex presents 12-week results from Barzolvolimab Phase 2 study in CSU
- Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
- Biotech Alert: Searches spiking for these stocks today
- TipRanks’‘Perfect 10’ List: These 2 Biotech Stocks Look Compelling at Current Levels